External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Sun Pharmaceutical Industries / Equity Bottom-Up

<ul><li>Sun Pharma (SUNP) is expected to sustain steady growth momentum, driven by strong traction in its global specialty business (18% of sales)</li><li>This growth is underpinned by the scale-up of its key products (Ilumya, Winlevi, and Cequa), which is expected to maintain momentum in the near to mid-term</li><li>However, uncertainty remains around the launch timeline of its specialty drug Leqselvi (Deuruxolitinib, approved in July 2024), due to ongoing patent litigation</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Sun Pharma (SUNP) is expected to sustain steady growth momentum, driven by strong traction in its global specialty business (18% of sales)This growth is underpinned by the scale-up of its key products (Ilumya, Winlevi, and Cequa), which is expected to maintain momentum in the near to mid-termHowever, uncertainty remains around the launch timeline of its specialty drug Leqselvi (Deuruxolitinib, approved in July 2024), due to ongoing patent litigationContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sun Pharmaceutical Industries: Specialty and Domestic Formulation to Drive Growth.